New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
Janus kinases (JAK) are a family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) that transduce cytokine-mediated signals through the JAK-STAT metabolic pathway. These kinases act by regulating the transcription of specific genes capable of inducing biological responses in several immune cell subse...
Saved in:
Main Authors: | Annalisa Marcuzzi (Author), Erika Rimondi (Author), Elisabetta Melloni (Author), Arianna Gonelli (Author), Antonio Giacomo Grasso (Author), Egidio Barbi (Author), Natalia Maximova (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
by: Paul Smith, et al.
Published: (2021) -
JAK-STAT pathway inhibitors in dermatology
by: Hélio Amante Miot, et al.
Published: (2023) -
Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
by: Birao Fan, et al.
Published: (2022) -
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
by: Eduardo Huarte, et al.
Published: (2021) -
Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
by: Marco Cattalini, et al.
Published: (2021)